Lupin receives FDA all-clear for Mandideep API manufacturing facility
Company becomes the fourth Indian pharma firm to secure FDA clearance in the last two weeks
Lupin has become the latest Indian pharmaceutical company to receive a clean bill of health from the US Food and Drug Administration for an active pharmaceutical ingredients (API) manufacturing facility.
On Wednesday, Lupin said it received an Establishment Inspection Report for its Mandideep Unit II plant from the US drug regulator with a Voluntary Action Indicated classification. The inspection at the facility was carried out between November 26, 2018 and December 4, 2018.
A VAI inspection classification indicates that the FDA will not take or recommend regulatory or enforcement action because any objectionable conditions found were not serious enough for it to do so.
“We are pleased to have received the EIR for our Mandideep Unit II facility, our important cardiovascular API manufacturing facility,” said Nilesh Gupta, Managing Director, Lupin. “We remain committed to enhancing compliance and quality standards across all our manufacturing sites.”
Earlier this week, Lupin received another EIR from the FDA for its largest and most-advanced oral solid dosage facility at Nagpur for an inspection carried out between January 6 and January 10, 2020.
Three other Indian companies have been given the FDA all-clear after API facility inspections over the last few days.
Dr. Reddy’s Laboratories received an EIR for its Plant-5 in Miryalaguda of Nalgonda District in Telangana, as did Strides Pharma for its Bengaluru plant. Meanwhile Biocon’s plant in Malaysia which manufactures insulin was also cleared by the FDA.
The robustness of international pharmaceutical supply chains has come into sharp focus recently – particularly from key API producers such as India and China -- as the COVID-19 pandemic continues to spread around the world.
Last week, India relaxed an export ban on anti-malarial drug hydroxychloroquine just 24 hours after US President Donald Trump warned of “retaliation” if the measure was not lifted. However, it is understood that Indian exports of the drug -- which has shown promise in treating patients with COVID-19, but is not currently approved as a therapy for the disease -- will only be made available to foreign governments and not private companies.
Related News
-
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: -
News Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities. -
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance